The HERPUD1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma cell line. This product provides a powerful loss-of-function model for investigating the role of HERPUD1 in endoplasmic reticulum (ER) stress signaling and ER-associated degradation (ERAD). Created through CRISPR/Cas9-mediated gene disruption, the polyclonal population comprises a diverse pool of edited cells, enabling robust and reproducible studies without clonal artifacts. The knockout model facilitates dissection of HERPUD1-dependent mechanisms in a disease-relevant epithelial background.
The A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a well-characterized model of human lung cancer. These cells exhibit properties of alveolar type II epithelial cells and recapitulate key features of lung adenocarcinoma, including tumorigenic potential and sensitivity to chemotherapeutic agents. The A-549 background offers a clinically relevant platform for studying ER stress responses in the context of cancer biology, drug resistance, and tumor progression.
HERPUD1 encodes an ER-resident protein that functions as a critical component of the ERAD pathway. It recognizes misfolded glycoproteins and facilitates their retrotranslocation and proteasomal degradation, thereby protecting cells from ER stress-induced apoptosis. HERPUD1 is transcriptionally regulated by the UPR sensors ATF6 and XBP1 and operates downstream of ER stress stimuli such as tunicamycin and thapsigargin. It forms complexes with core ERAD machinery including HRD1, SEL1L, VCP, DERL1, and OS9, linking substrate recognition to the proteasome. Disruption of HERPUD1 impairs clearance of ERAD substrates, leading to accumulation of misfolded proteins and activation of downstream UPR effectors like CHOP, GRP78/BiP, PERK, and IRE1.
In A-549 cells, HERPUD1 knockout generates a unique tool to interrogate ER stress resilience and ERAD function in lung adenocarcinoma. Given that cancer cells often rely on robust protein quality control to cope with high secretory demands and proteotoxic stress, this model allows researchers to assess how loss of HERPUD1 sensitizes tumor cells to ER stress-inducing drugs or alters malignant phenotypes. It provides insights into the interplay between ER homeostasis and oncogenic signaling, potentially uncovering synthetic lethal targets for therapeutic intervention.
This polyclonal knockout cell population is ideally suited for a wide range of experimental applications. Researchers can employ western blotting to monitor UPR markers such as CHOP and BiP, perform RT-qPCR to quantify ER stress gene expression changes, and conduct apoptosis assays to evaluate sensitivity to ER stress. Co-immunoprecipitation experiments can probe the integrity of the ERAD complex in the absence of HERPUD1, while proteasomal activity assays measure functional degradation capacity. Immunofluorescence-based approaches enable visualization of ER morphology and stress granule formation. These applications support mechanistic studies in cancer biology, drug sensitivity profiling, and the development of therapies targeting ER stress-related disorders. For additional details, please contact Ascent Research.
